Henry M. Jackson Foundation for the Advancement of Military Medicine

Leonardo DRS Celebrates Five Years of Going Pink at AUSA to Raise Money for Military Women and Family Members Suffering from Breast Cancer

Retrieved on: 
Friday, October 6, 2023
Women, Defense, Oncology, Health, Philanthropy, Consumer, Veterans, Fund Raising, How to Look Good Naked, Leonardo, Henry M. Jackson Foundation for the Advancement of Military Medicine, Quality of life, Looking Good, Feeling Gorgeous, Hope, Breast cancer, Military, Leonardo DRS, Social responsibility, Exhibition, Disease, Cancer, AUSA, HJF, Cosmetics, Wall, Friends, Defense News, The Look, Military medicine, Skin, Woman, Life, Patient, United States Department of the Army, Breast Cancer Awareness Month, Birth control, Nightclub, DRS

Leonardo DRS, Inc. (NASDAQ: DRS) announced today that it will celebrate its fifth year of sponsoring the “Stick It to Cancer” fundraiser at the United States Army (AUSA) expo in Washington, D.C. to recognize Breast Cancer Awareness Month, and support military members and their families dealing with breast cancer.

Key Points: 
  • Leonardo DRS, Inc. (NASDAQ: DRS) announced today that it will celebrate its fifth year of sponsoring the “Stick It to Cancer” fundraiser at the United States Army (AUSA) expo in Washington, D.C. to recognize Breast Cancer Awareness Month, and support military members and their families dealing with breast cancer.
  • Leonardo DRS is again partnering with The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) to raise awareness of breast cancer.
  • DRS will donate to HJF to support its breast cancer programs including the Look Good, Feel Better program, which gives active and retired military women, men, and family members affected by breast cancer an improved quality of life as they undergo and recuperate from cancer treatment.
  • For every sticker placed on the Wall, DRS will donate $10 dollars to HJF to support breast cancer programs including the Look Good, Feel Better program, up to $20,000.

Lane Health and United Care Consortium Establish Strategic Partnership to Help Unlock Healthier Futures

Retrieved on: 
Monday, June 12, 2023
Partnership, Commuting, Currency strap, Henry M. Jackson Foundation for the Advancement of Military Medicine, Health insurance

NORFOLK, Va., June 12, 2023 /PRNewswire-PRWeb/ -- Lane Health and United Care Consortium announced today they have entered into an agreement for Lane Health to provide their innovative benefit spending account solutions to United Care Consortium clients. Through this strategic partnership, United Care Consortium clients can offer their employees Lane Health's health savings accounts (HSAs), flexible spending accounts (FSAs) and Commuter accounts, as well as the groundbreaking Advance¹ line of credit, issued by WebBank.

Key Points: 
  • Through this partnership, Lane Health's benefit spending account solutions and the groundbreaking Advance¹ line of credit will be made available to United Care Consortium clients.
  • NORFOLK, Va., June 12, 2023 /PRNewswire-PRWeb/ -- Lane Health and United Care Consortium announced today they have entered into an agreement for Lane Health to provide their innovative benefit spending account solutions to United Care Consortium clients.
  • Through this strategic partnership, United Care Consortium clients can offer their employees Lane Health's health savings accounts (HSAs), flexible spending accounts (FSAs) and Commuter accounts, as well as the groundbreaking Advance¹ line of credit, issued by WebBank.
  • "We're thrilled to partner with United Care Consortium to help make healthcare more accessible and help their clients' employees better manage their out-of-pocket healthcare costs," said Scott Beck, Chief Revenue Officer at Lane Health.

BPGbio Announces New Partnership with DoD Focused on AI-Guided Breast Cancer Diagnostics

Retrieved on: 
Monday, May 22, 2023
Oncology, Health, Technology, Neurology, Artificial Intelligence, Pharmaceutical, Biotechnology, Windber Research Institute, Prostate cancer, BPH, Breast cancer, HJF, CBCP, Military medicine, Woman, Research, Interrogative, USU, Patient, Henry M. Jackson Foundation for the Advancement of Military Medicine, Outline of health sciences, AI, Rare, PSA, ER, Medical imaging

BPGbio’s Interrogative Biology ® Platform will complete comprehensive omics analysis and assessment using tissue and plasma/serum samples from a CBCP-supported program focused on breast cancer research.

Key Points: 
  • BPGbio’s Interrogative Biology ® Platform will complete comprehensive omics analysis and assessment using tissue and plasma/serum samples from a CBCP-supported program focused on breast cancer research.
  • The Interrogative Biology® Platform will also provide expanded assessment of BPGbio’s novel breast cancer diagnostic 34 gene panel with a focus on ER+ breast cancers, which are significantly on the rise.
  • “We are pleased to collaborate with BPGbio and use their AI and diagnostic platform to aid patients afflicted with breast cancer,” said Joseph Caravalho , Jr., M.D., HJF’s President and CEO.
  • “The BPGbio team has exceptional expertise in translating comprehensive omics analysis into effective diagnostic products for various cancer indications, which improves the lives of the patients we serve.”

ExThera Medical Successfully Completes Phase I of PURIFY RCT: US Investigational Device Exemption Trial Evaluating Seraph 100 for the Treatment of Septic Shock

Retrieved on: 
Tuesday, April 18, 2023
Research, General Health, Professional Services, Pharmaceutical, Medical Devices, Infectious Diseases, Data Analytics, Clinical Trials, Science, Biotechnology, FDA, Health, Other Science, Seraph, RCT, Clinical trial, Shock, Uniformed Services University of the Health Sciences, Trial of the century, Data analysis, Patient, Outline of health sciences, Department of Defense Serum Repository, Septic, United States Department of the Air Force, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bloodstream infections, Safety, Pharmaceutical industry

Data is now being collected and analyzed to submit to the FDA toward approval, allowing continuation of this pivotal study.

Key Points: 
  • Data is now being collected and analyzed to submit to the FDA toward approval, allowing continuation of this pivotal study.
  • Upon FDA approval to expand enrollment, PURIFY RCT will proceed to the critical phase of enrollment, the final clinical study required by the FDA for clearance to treat bloodstream infections in septic patients.
  • The clinical trial will be conducted in centers across the United States, targeting improvements in both clinical outcome and health economic endpoints.
  • “Completion of this first phase of evaluating the safety of Seraph 100 in treating pathogen associated shock is an exciting milestone,” said Mink Chawla, M.D., and Chair of the ExThera Medical Scientific and Medical Advisory Board.

BPGbio Announces Oncology Drug Pipeline and Prostate Cancer Biomarker Developments at AACR

Retrieved on: 
Wednesday, April 12, 2023
Research, Technology, Infectious Diseases, Neurology, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Uniformed Services University of the Health Sciences, Nintendo Integrated Research & Development, AACR, Therapy, Molecule, Georgetown University School of Medicine, Polymerization, Autonomous university, American Association for Cancer Research, Military medicine, Henry M. Jackson Foundation for the Advancement of Military Medicine, Biochemistry, Secretaria Nacional de Ciencia y Tecnologia, Cell biology, MD, Prostate, Risk, Walter Reed National Military Medical Center, Outline of health sciences, MA, AI, Rare, PSA, National Autonomous University of Mexico, Biopsy, Pharmaceutical industry, Cancer

“BPGbio has continued to advance our research in both therapeutics and diagnostics through our Interrogative Biology platform,” said Niven R. Narain, Ph.D , President & CEO.

Key Points: 
  • “BPGbio has continued to advance our research in both therapeutics and diagnostics through our Interrogative Biology platform,” said Niven R. Narain, Ph.D , President & CEO.
  • “We are pleased to present our data on BRG-399 at AACR, which is showing promising advancements towards pan-cancer activity.
  • BRG399 is leading the new oncology drug pipeline for BPGbio including those uniquely targeting E2 enzymes.
  • BPGbio’s prostate health screening panel is a blood-based test, and it provides guidance in men with BPH/LUTS (enlarged prostate) to determine their risk of detecting aggressive prostate cancer, avoiding the need for unnecessary biopsies.

Maryland Businesses Reflect on Fruitful 2022 and Strong Start to 2023

Retrieved on: 
Tuesday, January 31, 2023
Linda, MII, SECU, Microsoft, SR, Education, Health, Workforce, Henry M. Jackson Foundation for the Advancement of Military Medicine, Peterson (company), Partnership, University System of Maryland, Daily Record, Maryland General Assembly, Community college, Longevity, Partner, Military medicine, IT service management, HJF, House, News, Potomac River, Memory, Acquisition, 2020 Maryland's 7th congressional district special election, Greater Baltimore Committee, University system, Morgan State University, Sinai Hospital, HBCU, AVD, Culture, Senate, USM, Growth, Organization, Woman, History, Maryland House of Delegates, Airline, Nursing, Management, Clutch

BALTIMORE, Jan. 31, 2023 /PRNewswire-PRWeb/ -- The Maryland Marketing Partnership, which helps drive Maryland's branding and marketing efforts to attract businesses, create jobs, and grow the state's economy, today shared a summary of the latest news from companies and organizations that are part of the partnership.

Key Points: 
  • "As we begin a new year, it fills me with great pride to watch our Maryland businesses cap 2022 off with success and start 2023 off with a bang," said Tom Riford, executive director of the Maryland Marketing Partnership.
  • Businesses here are always focused on long-term growth and longevity while continuing to strengthen their relationships with patrons and communities."
  • Through its funding and support, the Maryland Innovation Initiative (MII) continues to nurture tech-related businesses and retain a highly trained workforce.
  • The University System of Maryland (USM) , based in Baltimore and the state's public higher education system, was well-represented in both chambers of the 2023 Maryland General Assembly as they convened in early January.

Maryland Innovation Initiative to Partner with Leading Military Medicine Nonprofit

Retrieved on: 
Tuesday, January 10, 2023
Partnership, Henry M. Jackson Foundation for the Advancement of Military Medicine, HJF, Research, NSF, MOU, United States Department of Defense, MII, Military medicine, Congress, Entrepreneurship, Memorandum, Management

COLUMBIA, Md., Jan. 10, 2023 /PRNewswire/ -- TEDCO, Maryland's economic engine for technology companies, is pleased to announce a new collaboration between TEDCO's Maryland Innovation Initiative (MII) and The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF). The MII Pop-up Event will take place on February 8 at HJF home office in Bethesda, Md., including the signing of the Memorandum of Understanding (MOU) and speakers from MII, TEDCO and HJF leadership.

Key Points: 
  • "We're very proud of MII's successful track record when it comes to both collaboration and outcomes," said Dr. Arti Santhanam , executive director of MII.
  • "This MOU gives us the opportunity to expand on that success in partnership with the dedicated team at HJF.
  • Together, we anticipate advancing new business creation with crucial military medical applications."
  • Authorized by Congress in 1983 with the mission to advance military medicine, HJF has managed a portfolio of more than 13,000 research and development awards and 710 novel innovations since its inception.

HJF Leadership Forum Seeks to Ease Service Member-to-Veteran Transition Experience

Retrieved on: 
Wednesday, November 30, 2022
Wounded Warrior Project, Military medicine, Congressional Black Caucus Foundation, Henry M. Jackson Foundation for the Advancement of Military Medicine, Education, Veteran, Technology transfer, Defense, DRS, Health, Research, Federation, HJF, Walmart, Johnson & Johnson, Kaiser Permanente, Management

BETHESDA, Md., Nov. 30, 2022 /PRNewswire/ -- The HJF Leadership Forum, hosted by The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF), convened nearly 50 leaders from federal government, academia and private industry to discuss the challenges service members face as they transition from active duty to veteran status. HJF hosts such leadership convenings to foster discussion and action plans among public and private organizations on many topics, in the interest of advancing military medicine for service members and civilians alike.

Key Points: 
  • BETHESDA, Md., Nov. 30, 2022 /PRNewswire/ -- The HJF Leadership Forum, hosted by The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF), convened nearly 50 leaders from federal government, academia and private industry to discuss the challenges service members face as they transition from active duty to veteran status.
  • HJF hosts such leadership convenings to foster discussion and action plans among public and private organizations on many topics, in the interest of advancing military medicine for service members and civilians alike.
  • Invited speakers at the HJF Leadership Forum included:
    Drs.
  • The semi-annual HJF Leadership Forum series encourages coalition-building on topics vital to the health and medical readiness of the U.S. military.

US Military Health System Research Study Deploys Clinical ink's Self-Testing Mobile Platform to Understand Long COVID

Retrieved on: 
Tuesday, November 1, 2022
Military medicine, Henry M. Jackson Foundation for the Advancement of Military Medicine, Government budget balance, Population, Cognition, Uniformed Services University of the Health Sciences, USU, Cros, Efficiency, Biomarker, GLOBE, Research, Guest appearance, Time, COVID-19, Infection, Clinical, Technology, HJF, Patient, UX, Attention, Risk, Pharmaceutical industry, Medical device, Medicine, Immunity

The app is currently deployed in a study of the risk factors, symptoms, disease course, and clinical outcomes of COVID-19 among members of the US military population.

Key Points: 
  • The app is currently deployed in a study of the risk factors, symptoms, disease course, and clinical outcomes of COVID-19 among members of the US military population.
  • Study results have and will be further shared with Military Health System leaders and others with the goal of informing clinical care and practice guidelines for managing patients with COVID-19.
  • IDCRP is supported by The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF).
  • By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.

THE PROSTATE CANCER FOUNDATION ANNOUNCES 2022 YOUNG INVESTIGATOR AWARDS TOTALING $7.2 MILLION FOR PROSTATE CANCER RESEARCH

Retrieved on: 
Wednesday, October 26, 2022
Quality of life, Physician, Disease, Prostate, Prostate cancer, Genetic testing, Patient, Metastasis, AIM, Research, PCF, Military medicine, Prostate Cancer Foundation, Henry M. Jackson Foundation for the Advancement of Military Medicine, Outline of health sciences, Alpha particle, Death, Center, National Institute of Environmental Health Sciences, Exercise, Pharmaceutical industry, Medical imaging, Veteran, Doctor of Philosophy

LOS ANGELES, Oct. 26, 2022 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the Class of 2022 Young Investigator Award recipients totaling $7.2 million in funding for innovative prostate cancer research.

Key Points: 
  • LOS ANGELES, Oct. 26, 2022 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the Class of 2022 Young Investigator Award recipients totaling $7.2 million in funding for innovative prostate cancer research.
  • PCF Young Investigator Awards are intended to identify a cohort of future research leaders who will keep the field of prostate cancer research vibrant with new ideas and offer career and project support for early career physicians and scientists who are committed to advancing the prostate cancer field.
  • Thirty-four PCF Young Investigator Awards totaling $7.2 million were granted to the promising next generation of cancer researchers.
  • PCF is committed to creating a global public square for prostate cancer, in service to our mission of ending death and suffering from the disease.